Pharma Mar, S.A., a biopharmaceutical company, engages in the discovery and development of marine-derived anticancer drugs in Spain and internationally.
High growth potential and slightly overvalued.
Share Price & News
How has Pharma Mar's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: PHM's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: PHM exceeded the Spanish Biotechs industry which returned 39.4% over the past year.
Return vs Market: PHM exceeded the Spanish Market which returned 9.4% over the past year.
Price Volatility Vs. Market
How volatile is Pharma Mar's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StDo Directors Own Pharma Mar, S.A. (BME:PHM) Shares?
1 month ago | Simply Wall StIs There An Opportunity With Pharma Mar, S.A.'s (BME:PHM) 39% Undervaluation?
1 month ago | Simply Wall StPharma Mar (BME:PHM) Shareholders Have Enjoyed An Impressive 148% Share Price Gain
Is Pharma Mar undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: PHM (€4.77) is trading below our estimate of fair value (€5.98)
Significantly Below Fair Value: PHM is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: PHM is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: PHM is unprofitable, so we can't compare its PE Ratio to the Spanish market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate PHM's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: PHM is overvalued based on its PB Ratio (49.3x) compared to the ES Biotechs industry average (4.1x).
How is Pharma Mar forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PHM is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.4%).
Earnings vs Market: PHM is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: PHM's is expected to become profitable in the next 3 years.
Revenue vs Market: PHM's revenue (8.5% per year) is forecast to grow faster than the Spanish market (4.7% per year).
High Growth Revenue: PHM's revenue (8.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: PHM's Return on Equity is forecast to be very high in 3 years time (50.2%).
How has Pharma Mar performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PHM is currently unprofitable.
Growing Profit Margin: PHM is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: PHM is unprofitable, and losses have increased over the past 5 years at a rate of -37.5% per year.
Accelerating Growth: Unable to compare PHM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PHM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).
Return on Equity
High ROE: PHM's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
Return on Assets
Return on Capital Employed
How is Pharma Mar's financial position?
Financial Position Analysis
Short Term Liabilities: PHM has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: PHM has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: PHM has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: PHM's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Inventory Level: PHM has a high level of physical assets or inventory.
Debt Coverage by Assets: PHM has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: PHM has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if PHM has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Pharma Mar's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate PHM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate PHM's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if PHM's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PHM's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of PHM's dividend in 3 years as they are not forecast to pay a notable one for the Spanish market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
José María Fernández Sousa-Faro 0
Mr. José María Fernández Sousa-Faro, Ph.D., founded Pharma Mar, S.A.U. in 1986. He Founded Noscira, S.A., in 2000. Mr. Fernández Sousa-Faro serves as the Chief Executive Officer and President of Pharma Mar ...
CEO Compensation Analysis
Compensation vs Market: José María's total compensation ($USD0.00) is below average for companies of similar size in the Spanish market ($USD902.02K).
Compensation vs Earnings: José María's compensation has increased whilst the company is unprofitable.
|Executive Vice-Chairman||0yrs||€124.00k||0.63% €6.6m|
|0yrs||no data||no data|
|Chief Financial Officer||20.1yrs||no data||no data|
|Chief Operating Officer||3.3yrs||no data||no data|
|Director of Finance & Administration||11.8yrs||no data||no data|
|Director of Investor Relations & Capital Markets||5.1yrs||no data||no data|
|Director of Marketing and Sales||7yrs||no data||no data|
|Director of Human Resources & Information Technologies||16.6yrs||no data||no data|
|Managing Director of Oncology Business Unit||12.8yrs||no data||no data|
Experienced Management: PHM's management team is seasoned and experienced (11.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Pharma Mar, S.A.'s company bio, employee growth, exchange listings and data sources
- Name: Pharma Mar, S.A.
- Ticker: PHM
- Exchange: BME
- Founded: 1986
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: €1.054b
- Shares outstanding: 221.23m
- Website: https://www.pharmamar.com
Number of Employees
- Pharma Mar, S.A.
- Avenida de los Reyes, 1
- Pol. Industrial La Mina – Norte
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|PHM||BME (Bolsas y Mercados Espanoles)||Yes||Bearer Shares||ES||EUR||Nov 2015|
|PHME||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Bearer Shares||GB||EUR||Nov 2015|
|PMR||DB (Deutsche Boerse AG)||Yes||Bearer Shares||DE||EUR||Nov 2015|
|0RC6||LSE (London Stock Exchange)||Yes||Bearer Shares||GB||EUR||Nov 2015|
|PHMM.F||OTCPK (Pink Sheets LLC)||Yes||Bearer Shares||US||USD||Nov 2015|
|PHM1 N||BMV (Bolsa Mexicana de Valores)||Yes||Bearer Shares||MX||MXN||Nov 2015|
Pharma Mar, S.A., a biopharmaceutical company, engages in the discovery and development of marine-derived anticancer drugs in Spain and internationally. The company operates through two segments, Biopharmaceuticals and Consumer Chemicals. It develops and commercializes Yondelis for the treatment of soft tissue sarcomas and for ovarian cancer. The company also develops clinical-stage programs, including Aplidin, Zepsyre, PM184, and PM14. In addition, it develops and markets diagnostics kits; and produces and markets insecticides and air fresheners for household use and household products. Pharma Mar, S.A. was founded in 1986 and is based in Madrid, Spain.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/18 22:52|
|End of Day Share Price||2020/02/18 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.